Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicenter study by the Spanish Psoriasis Group

Autor: Del Alcazar E, Suarez-Perez J, Armesto S, Rivera R, Herrera-Acosta E, Herranz P, Martin I, Montesinos E, Hospital M, Vilarrasa E, Ferran M, Ruiz-Villaverde R, Sahuquillo-Torralba A, Ruiz-Genao D, Perez-Barri S, Munoz C, Llamas M, Valenti F, Josune Mitxelena M, Lopez-Ferrer A, Carretero G, Vidal D, Mollet J, Belinchon I, Manuel Carrascosa J

Publikováno v: Journal of the European Academy of Dermatology and Venereology : JEADV
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname

BACKGROUND: Little has been published on the real-world effectiveness and safety of apremilast in psoriasis.; OBJECTIVES: To evaluate the effectiveness, safety, and drug survival of apremilast at 52 weeks in patients with moderate to severe plaque ps

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::5f769aa78066e388fbf4cb49284c3e1a
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=4489